Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
AMV564
BIOLOGICAL
2 trials
Sponsors
Amphivena Therapeutics, Inc.
Conditions
Acute Myeloid Leukemia
Locally Advanced or Metastatic Solid Tumors
Phase 1
Study of AMV564 in Patients With AML
Completed
NCT03144245
Amphivena Therapeutics, Inc.
Acute Myeloid Leukemia
Start: 2017-03-20
End: 2020-11-05
Updated: 2021-10-12
Study of AMV564 in Subjects With Advanced Solid Tumors
NCT04128423
Amphivena Therapeutics, Inc.
Locally Advanced or Metastatic Solid Tumors
Start: 2019-10-09
End: 2021-12-31
Target: 65
Updated: 2021-10-19
Related Papers
849 ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity
Regular and Young Investigator Award Abstracts
2021-11-01
1 citations
887 Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade
Regular and Young Investigator Award Abstracts
2021-11-01
Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.
Journal of Clinical Oncology
2021-05-20
7 citations
372 Single-agent anti-tumor activity in relapsed/refractory solid tumors: interim data from the phase 1 solid tumor trial of AMV564, a novel T-cell engager
Regular and Young Investigator Award Abstracts
2020-11-01
3 citations
692 AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response
Regular and Young Investigator Award Abstracts
2020-11-01
A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.
Journal of Clinical Oncology
2020-05-20
2 citations
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Blood
2019-11-13
67 citations
S877 SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T‐CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST‐IN‐HUMAN TRIAL
HemaSphere
2019-06-01
9 citations
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Blood
2018-11-29
22 citations
AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia
Blood
2018-11-29
5 citations
Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro
Blood
2017-12-07
15 citations